South Street Advisors LLC Reduces Position in Halozyme Therapeutics, Inc. $HALO

South Street Advisors LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 231,758 shares of the biopharmaceutical company’s stock after selling 16,094 shares during the period. Halozyme Therapeutics comprises approximately 2.2% of South Street Advisors LLC’s holdings, making the stock its 21st biggest holding. South Street Advisors LLC’s holdings in Halozyme Therapeutics were worth $15,597,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Empowered Funds LLC purchased a new stake in Halozyme Therapeutics during the first quarter valued at about $755,000. Acadian Asset Management LLC purchased a new position in shares of Halozyme Therapeutics in the first quarter worth $195,000. Hsbc Holdings PLC increased its stake in shares of Halozyme Therapeutics by 117.1% in the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 5,448 shares during the period. EverSource Wealth Advisors LLC increased its holdings in Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 174 shares during the period. Finally, Baird Financial Group Inc. increased its holdings in Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 650 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $68.18 on Friday. The stock has a 50 day moving average of $66.09 and a 200 day moving average of $68.77. Halozyme Therapeutics, Inc. has a 12 month low of $51.06 and a 12 month high of $82.22. The firm has a market cap of $8.09 billion, a PE ratio of 24.53, a PEG ratio of 0.28 and a beta of 0.89. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same period in the prior year, the company earned $1.11 earnings per share. The firm’s revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 7.6 EPS for the current fiscal year.

Insider Activity

In other news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $69.19, for a total value of $691,900.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $53,122,698.20. This trade represents a 1.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total transaction of $599,087.48. Following the sale, the chief operating officer owned 7,055 shares of the company’s stock, valued at $477,200.20. The trade was a 55.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 120,482 shares of company stock valued at $8,200,842 in the last ninety days. Insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of a number of research analyst reports. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Benchmark lifted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Finally, HC Wainwright lifted their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $80.67.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.